Passage of paracetamol into breast milk and its subsequent metabolism by the neonate

Similar documents
The excretion of zopiclone into breast milk

EFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

PRODUCT INFORMATION Panadeine EXTRA

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PANADOL EXTRA PRODUCT INFORMATION

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:

Metronidazole excretion in human milk and its

Metabolism Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

paracetamol overdose: evidence for early hepatocellular damage

Flecainide excretion in human breast milk

Chapter 4. Drug Biotransformation

Summary of Product Characteristics

A HISTOPATHOLOGICAL STUDY OF ANALGESIC HEPATOTOXICITY IN RABBIT

The disposition of primidone in elderly patients

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION

Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol

Drug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

Summary of Product Characteristics

Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate

PARACOD Tablets (Paracetamol + Codeine phosphate)

PANADOL OSTEO PRODUCT INFORMATION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION

Effect of Histamine H2-receptor Antagonists on. Acetaminophen and its Metabolites in Human Plasma

Figure 1 The structure of antipyrine (1 -phenyl-2,3- groups, have looked at the factors which influence. antipyrine metabolism in man.

The dependence of paracetamol absorption on the rate of gastric emptying

DATA SHEET. PANADOL Mini Caps Capsule shaped tablet with a gelatin coating which is one half green and the other half white.

Pharmacokinetics of paracetamol after

AUSTRALIAN PRODUCT INFORMATION PANADOL OPTIZORB TABLETS (PARACETAMOL) TABLETS PANADOL OPTIZORB CAPLETS (PARACETAMOL) TABLETS

KELFER Capsules (Deferiprone)

N-monodesmethyldiltiazem is the predominant metabolite of

NEW ZEALAND DATASHEET

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.

CHILDREN S PANADOL COLOURFREE SUSPENSION PANADOL SUPPOSITORIES 125 MG PANADOL SUPPOSITORIES 250 MG DATA SHEET. Proprietary (Trade) Name: PANADOL

KINETICS AND METABOLISM

Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

AUSTRALIAN PRODUCT INFORMATION, PAINSTOP DAY-TIME PAIN RELIEVER (PARACETAMOL 120MG IN 5ML AND CODEINE PHOSPHATE HEMIHYDRATE 5MG IN 5ML)

Mechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo

Industrial Toxicology

KELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg

a very short half-life, but its main metabolite, which

Paracetamol poisoning in children and hepatotoxicity

SUMMARY OF PRODUCT CHARACTERISTICS. Each ml of solution for infusion contains 10 mg of paracetamol.

Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):

Committee for Risk Assessment RAC. Annex 3 Records of the targeted public consultation on the reproductive toxicity of.

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

AROMASIN 25mg (Tablets)

PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET

Disposition of metronidazole and its effects on sulphasalazine

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET

Population studies on Gilbert's syndrome

Abiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).

ENVIRONMENTAL TOXICOLOGY

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Introduction to Pharmacokinetics

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

Cimetidine Protects Against Acetaminophen Hepatotoxicity in Rats

Acetaminophen. TIP Session IV

PRODUCT INFORMATION PANADOL TABLETS PANADOL MINI CAPS PANADOL SUPPOSITORIES

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

COMPARISON OF PLASMA AND SALIVA LEVELS OF METOPROLOL AND OXPRENOLOL

ACETYLCYSTEINE INJECTION

PRESCRIBING INFORMATION mg primaquine phosphate equivalent to 15 mg primaquine base. Antimalarial

Metabolic Changes of Drugs and Related Organic Compounds

EXCRETION OF PARACETAMOL AND ITS METABOLITES IN MAN

PARACIP Injection (Paracetamol )

The disposition of ketoprofen enantiomers in man

Ibuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)

PRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets

Immodium / loprarmide

Paediatric Clinical Chemistry

PRODUCT INFORMATION. Codral* Original Cold & Flu Tablets

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

Posology. Posology and Dosage Regimen: Factors Affecting Drug Dosage: 08/09/ ) Age: 1. Young s Rule, based on age:

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives

Long term high dose morphine, ketamine and midazolam infusion in a child with burns

Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme

Konakion MM. Phytomenadione Composition. Properties and effects. Pharmacokinetics

50% Concentrated Injection

Pharmacokinetics of ibuprofen in man. I. Free and total

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol)

The Effects of Methionine on Paracetamol Induce Live Injury Hepatomegaly- (Animal Study)

Summary of Product Characteristics

Intestinal metabolism of ethinyloestradiol and paracetamol

INTEGRATIVE MEDICINE URINE, SPOT Result Range Units

Toxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine

Impairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency

Transcription:

Br. J. clin. Pharmac. (1987), 24, 63-67 Passage of paracetamol into breast milk and its subsequent metabolism by the neonate L. J. NOTARIANNI1, H. G. OLDHAM2 & P. N. BNNTT' 'School of Pharmacy and Pharmacology, University of Bath, and Clinical Pharmacology Unit, Royal United Hospital, Bath, 2DMPK, Smith Kline and French Research Ltd, The Frythe, Welwyn, Hertfordshire 1 Paracetamol was administered to nursing mothers. The drug passed rapidly into milk and the milk:plasma concentration ratio was approximately unity. 2 The estimated maximum dose to the neonate was 1.85% of the weight-adjusted maternal oral dose of paracetamol 1.0 g. Recovery of paracetamol was greater from the breast from which samples were taken frequently than from the breast which was sampled only once. 3 Paracetamol, its glucuronide, sulphate, cysteine and mercapturate conjugates were found in the urine of the neonates although only the parent drug was detected in breast milk. 4 The neonates excreted significantly greater proportions of unchanged paracetamol (P < 0.01) and significantly lesser proportions of paracetamol sulphate (P < 0.001) than did healthy volunteers aged 11-80 years who received a therapeutic dose of paracetamol. 5 The findings are compatible with a deficiency of sulphate conjugation by the neonate. Keywords paracetamol neonate metabolism breast milk biotransformation Introduction Paracetamol is widely used as a post-partum analgesic in nursing mothers (Passmore et al., 1984; Matheson, 1985). It is believed to present no risk to the suckling infant since less than 0.25% of a maternal single dose is estimated to reach the child (Berlin et al., 1980; Bitzen et al., 1981). As many drug metabolic reactions are deficient in the newborn (Rane & Wilson, 1983), ingestion of seemingly small quantities of drug may assume importance. Levy et al. (1975) and Miller et al. (1976) found that neonates had limited capacity to conjugate paracetamol with glucuronic acid but that sulphate conjugation was well developed. Methods Subjects The following were studied: (a) Four volunteer nursing mothers (a,b,c,d) 63 aged 26-37 years and 2-8 months post-partum, breast-fed their babies in the Clinical Pharmacology Unit, Royal United Hospital, Bath. ach mother then received paracetamol 1.0 g as a single dose by mouth. Blood and milk samples were taken concurrently every 30 min for 3.0-3.5 h thereafter, the milk being taken from the same breast each time by means of an electricallydriven breast pump which extracted all the available milk. No samples were taken from the other breast until the end of the study when all available milk was extracted from it also. (b) Paired milk and blood samples were obtained from nine nursing mothers aged 20-38 years, 2-10 days after delivery; each had received paracetamol (1.0-2.0 g) in the preceding 12 h for post-partum pain. (c) Six infants (2-6 days old) of five mothers aged 28-30 years (,F,G,H,I) (one with twins) who took paracetamol for post-partum pain, were studied. The infants received paracetamol

64 L. J. Notarianni, H. G. Oldham & P. N. Bennett via the breast milk and neither the dose administered to the mother nor the timing of the feed after dosing was influenced by the requirements of the study in any way. The mothers received paracetamol (1.0-2.0 g) 2.0-4.0 h before breast feeding; immediately after each infant had suckled, a 'Coloplast' baby urine collector was applied to it and urine was collected for 1.0-3.5 h (Table 1). (d) Forty-nine healthy male and female volunteers aged 11-80 years, comprising hospital and university staff and fit elderly patients contacted from general practitioner lists, received paracetamol 0.5 g or 1.0 g as a single oral dose. Paracetamol and metabolites were assayed in urine collected over the next 8 h. All the studies were approved by the ethics committee of the Bath Health District. Samples The ph and volume of each milk sample were measured immediately upon collection and milk, plasma and urine samples were stored at -20 C prior to analysis. Analyses Paracetamol (P) and its glucuronide (PG), sulphate (PS), cysteine (PC), and mercapturic acid (PM) metabolites were assayed by high performance liquid chromatography using a modification of the method of Adriaenssens & Prescott (1978). The values for each metabolite were converted to the equivalent weight of paracetamol from which it was derived by correction for molecular weight. All values were then expressed as a percentage of the total recovery. Standard metabolites were the gift of Dr R. Andrews, Sterling Winthrop R & D, Newcastle. The calibration curves were linear over the range 0.2-30 mg 1-1 (paracetamol), and 0.5-50 mg 1P1 (metabolites). The coefficients of variation at 0.5 mg 1-1 were 6% (paracetamol) and 8% (metabolites). Calculations The areas under the concentration-time curves were calculated by the trapezoidal rule to the last datum point. Results (a) Figure 1 shows milk and plasma concentration-time profiles in the volunteers who took paracetamol 1.0 g by mouth (Subjects, a). Following its ingestion by the mother, paracetamol rapidly entered milk and the milk concentration exceeded that in plasma in each volunteer. The mean area (± s.e. mean) under the milk concentration-time curve was 21.10 ± 4.63 mg 1-1 h and that for plasma was 13.08 ± 2.75 mg I-1 h. The mean milk:plasma concentration ratio for 21 paired samples in the four volunteers was 1.24 + 0. 12; this value refers to mature milk. Seven milk samples (at least one from each mother) were assayed for metabolites of paracetamol but none was detected, the limit of detectability being < 100 ng ml-'. Figure 2 shows that both the concentration of paracetamol in milk and the milk volumes were higher in the breast that was expressed every 30 min for 3.0-3.5 h, compared with the breast that was sampled only once at the end of the collection period. Table 1 Recovery of paracetamol and its metabolites in the urine of breast-fed neonates Paracetamol Dose-feed Urine and metabolites Dose interval collection in urine of Mother (g) (h) time (h) neonate (,ug) 1 3.5 3.0 85.2 F 1 3.2 3.5 59.8 G(1)* 1 2.0 2.5 27.6 G(2)* 1 2.0 1.0 486.6 H 2 4.0 3.0 822.2 I 2 4.0 3.5 921.9 Urine collections commenced immediately after feeding had been completed. Paracetamol recovered includes all metabolites corrected for molecular weight. * Indicates twin babies; the infant G(2) produced 10.5 ml urine compared to 0.6 ml by his sister.

Paracetamol in milk and metabolism by neonate 65 a 14F b 14 lo0 io0-6 6 a) cg Ic X 10 a. )_- 2 6 21 Time (h) Figure 1 Milk (L) and plasma (0) concentrations of paracetamol in four volunteers after administration of paracetamol 1.0 g by mouth. L 10r 27.6-921.9,ug (mean ± s.e. mean, 400.6 ± 164.5,ug); the large variation reflects differences in 8- * (60) urine volume, collection time, dose received and the interval from dose to feed. The recovery of 0) 6 paracetamol and its metabolites in these infants (37) is presented in Table 2. All the babies excreted *(55) 0(9 5) paracetamol, PG and PS, but PC or PM were not co 0(9*5) found in every urine. The major metabolite was 0) 0(25) 0(25) PG, followed in decreasing proportion by para- CL2 0(16) cetamol, PC + PM, and PS. Since no metabolites were detected in milk, it was assumed that these products were synthesised by the neonates. a b c d (d) A summary of the percentages of paracetamol and its metabolites recovered from the Figure 2 Paracetamol concentr from breasts emptied at 30 min itntervals (m) and after urine of healthy volunteers (Subjects, d) also single expression at 3.0-3.5 h (o ) in volunteers a,b,c appears in Table 2. The neonates excreted a and d. The figures in brackets givve the volume of milk significantly greater proportion of paracetamol obtained (ml). (b) The mean milk:plasnna ratio for para- reported elsewhere. cetamol in the samples obtained from nine mothers who took the drug for therapeutic purposes (Subjects, b) was 0.95 ± 0.16; this value Discussion refers to colostrum and transitional milk and was not significantly different from that obtained in mature milk (Subjects, a). (c) Table 1 shows that the total amount of paracetamol and its metabolites excreted by the neonates in their urine (Subjects, c) ranged from (P < 0.01) and a significantly lesser proportion of PS (P < 0.001) than did the volunteers. Full details of the findings in the volunteers will be The factors that govern drug passage into breast milk are likely to be those that influence drug transfer elsewhere in the body. The physical characteristics of paracetamol suggest that the drug should diffuse readily into milk for it has a

66 L. J. Notarianni, H. G. Oldham & P. N. Bennett Table 2 Percentage recovery of paracetamol and its metabolites in the urine of neonates and of healthy volunteers aged 11-80 years P PG PS PC+PM Neonates (n = 6) Mean 24.9 54.1 9.9 11.1 s.e. mean 6.6 6.0 1.9 3.2 Range 9.5-46.9 32.8-71.3 5.0-18.3 0-20.5 Healthy volunteers (n = 49) Mean 5.2 52.1 35.1 7.4 s.e. mean 0.7 1.4 1.5 0.5 Healthy volunteers took paracetamol 0.5 g (n = 2) or 1 g (n = 47) by mouth; urine was collected for 8 h. Neonates received paracetamol indirectly via the breast milk. pka of 9.5, is largely unionised at physiological ph and binding to plasma proteins is low. Our data show that paracetamol passes rapidly into milk and the milk:plasma concentration ratio is approximately unity. Other workers have made similar findings (Berlin et al., 1980; Bitzen et al., 1981; Findlay et al., 1981). The amount of paracetamol received by the suckling infant in a feed may be calculated as a percentage of the weight-adjusted maternal dose received in this study or as a percentage of the lowest recommended infant single dose. In order to do so it is assumed that: a) the milk intake is 150 ml kg-' day-', as at peak lactation, b) the infant suckles five times a day, c) the maternal weight is 60 kg and d) the lowest recommended single infant dose is 60 mg (British National Formulary, 1986) In the volunteer mothers (Methods, Subjects, a) the mean maximum concentration of paracetamol in milk was 10.3 ± 1.3 mg 1'1 and the average concentration was 6.1 ± 0.8 mg I-1. On this basis, an infant suckling once at the time of peak milk paracetamol concentration would receive 1.85% (or on average 1.1%) of the weight-adjusted maternal single dose. Similarly, an infant which suckles once at the peak paracetamol concentration would receive 0.52% of the lowest recommended infant single dose. Clearly these estimates may not be taken to apply when paracetamol is used in repeated doses and there are no literature data on which to base an estimate of the exposure of the infant to paracetamol under such conditions. The biotransformation of paracetamol in the adult is well established and the major metabolites are PG and PS (Prescott, 1980). A small proportion of the drug (<10% ) is oxidised by the mixed function oxidase system to a reactive intermediate(s) which conjugates with hepatic glutathione and appears in the urine as paracetamol cysteine (PC) and paracetamol mercapturic acid (PM) (Mitchell et al., 1973, 1974; Davis et al., 1976; Howie et al., 1977; Slattery & Levy, 1979). Any oxidised metabolite that does not combine with glutathione is a potential cause of cell damage. In our study of six infants who received paracetamol in breast milk, the parent drug, PG and PS were detectable in the urine of them all and PC and/or PM in 5. This finding contrasts with that of Berlin et al. (1980) who, also using an high performance liquid chromatographic method of analysis, failed to detect paracetamol or metabolites in the urine of nursing infants. We found that the infants excreted a significantly higher proportion of unchanged paracetamol but a lower proportion of PS than did 49 healthy volunteers who took a single oral dose of paracetamol (Table 2). Levy et al. (1975) who gave paracetamol 12 mg kg-1 by mouth to neonates and Miller etal. (1976) who gave 10 mg kg-' found that higher percentages of the dose were excreted as sulphate than as glucuronide. These studies employed both a larger dose of paracetamol and a longer period of urine collection than did the work we report; neither study gave data on PC or PM. Our findings thus differ from those previously reported and are compatible with a deficiency of sulphate conjugation by the neonate, although immaturity of

renal function may also contribute to the differences in the recoveries of paracetamol and of its metabolites between neonates and older subjects. Despite the increased excretion of the parent drug, no significant increase was noted in the products of cytochrome P-450 oxidation (PC+ PM) suggesting that there may be lower concentrations or lower activities of the mixed function oxidase system or glutathione transferase in neonates than in older subjects. Therefore, in infants, either the formation of the reactive metabolite or its detoxication may be incompletely developed. There was a significant increase in the amount of paracetamol (and milk) excreted from the Paracetamol in milk and metabolism by neonate 67 frequently sampled breast compared with that recovered from the breast that was sampled only once. This suggests that the quantity of paracetamol received in milk is dependent on milk flow and is a variable that should be taken into account in the design and interpretation of studies of drug passage into breast milk. The work was supported by grants from the Arthritis Research Council and Wessex Regional Health Authority. We are grateful to Mrs K. M. Cordall for help with laboratory assays and to Mrs S. J. Humphries for nursing assistance. References Adriaenssens, P. I. & Prescott, L. F. (1978). High performance liquid chromatographic estimation of paracetamol metabolites in plasma. Br. J. clin. Pharmac., 6, 87-88. Berlin, C. M., Yaffe, S. J. & Ragni, M. (1980). Disposition of acetaminophen in milk, saliva and plasma. Ped. Pharmac., 1, 135-141. Bitzen, P.-O, Gustafsson, B., Jostell, K. G., Melander, A. & Wahlin-Boll,. (1981). xcretion of paracetamol in human breast milk. ur. J. clin. Pharmac., 20, 123-125. Davis, M., Simmons, C. J., Harrison, N. G. & Williams, R. (1976). Paracetamol overdose in man: relationship between pattern of urinary metabolites and severity of liver damage. Quart. J. Med., 45, 181-191. Findlay, J. W. A., DeAngelis, R. L., Kearney, M. F., Welch, R. M. & Findlay, J. M. (1981). Analgesic drugs in breast milk and plasma. Clin. Pharmac. Ther., 29, 625-633. Howie, D., Adriaenssens, P. I. & Prescott, L. F. (1977). Paracetamol metabolism following overdosage: application of high performance liquid chromatography. J. Pharm. Pharmac., 29, 235-237. Levy, G., Khanna, N. N., Soda, D. M., Tsuzuki, 0. & Stern, L. (1975). Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics, 55, 818-825. Matheson, I. (1985). Drugs taken by mothers in the puerperium. Br. med. J., 290, 1588-1589. Miller, R. P., Roberts, R. J. & Fischer, L. J. (1976). Acetaminophen elimination kinetics in neonates, adults and children. Clin. Pharmac. Ther., 19, 284-294. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R. & Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. 1. Role of metabolism. J. Pharmac. exp. Ther., 187, 185-194. Mitchell, J. R., Thorgeirsson, S. S., Potter, W. Z., Jollow, D. J. & Keiser, H. (1974). Acetaminopheninduced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmac. Ther., 16, 676-684. Passmore, C., Mclnay, J. C. & D'Arcy, P. F. (1984). Drugs taken by mothers in the puerperium: inpatient survey in Northern Ireland. Br. med. J., 289, 1593-1596. Prescott, L. F. (1980). Kinetics and metabolism of paracetamol and phenacetin. Br. J. clin. Pharmac., 10 (Suppl. 2), 291-298S. Rane, A. & Wilson, J. T. (1983). Clinical pharmacokinetics in infants and children. In Handbook of clinical pharmacokinetics, eds Gibaldi, M. & Prescott, L. F., pp 142-167. Balgowlah, Australia: Adis Press. Slattery, J. T. & Levy, G. (1979). Acetaminophen kinetics in acutely poisoned patients. Clin. Pharmac. Ther., 25, 184-195. (Received 21 July 1986, accepted 5 March 1987)